Research
Hormonal
Probiotic supplementation can reduce systemic inflammation and oxidative stress, which are contributors to insulin resistance, by lowering pro-inflammatory cytokines and increasing antioxidant enzyme activity.
Some probiotic supplements may help lower chronic inflammation and oxidative stress in people with diabetes, which can indirectly support better insulin sensitivity.
ModerateSupportsMEDIUM confidence
The anti-diabetic effects of probiotics include reducing pro-inflammatory cytokines via a NF-κB pathway, reduced intestinal permeability, and lowered oxidative stress.
Why this rating
Supported by specific human trials cited (e.g., Ejtahed et al.) showing reduced inflammatory markers.
Source
Probiotics, prebiotics, synbiotics and insulin sensitivity
Y. A. Kim et al. · Nutrition Research Reviews · 2017
DOI 10.1017/s095442241700018x
narrative_reviewCited 319×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Short-chain fatty acids (SCFAs), particularly butyrate, produced by gut microbiota fermentation of prebiotics/probiotics, improve insulin sensitivity by activating G-protein-coupled receptors on L-cells to stimulate GLP-1 and PYY release.Good
- Administration of probiotics, prebiotics, or synbiotics can improve insulin sensitivity and glucose metabolism in humans, primarily through mechanisms involving short-chain fatty acid (SCFA) production, modulation of gut microbiota composition, and reduction of systemic inflammation.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →